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INTRODUCTION
Pharmaceutical research has recently focussed on developing delivery systems for macromolecules such as proteins, peptides and antigens as they become the preferred therapeutics because of their greater selectivity, lower disruption of normal biological processes and reduced clinical development time with a shorter United States Food and Drug Administration approval period. 1 However, to reach a therapeutic level most of these macromolecules must be administered repeatedly in an invasive manner. 2 The pulmonary delivery of macromolecules is a viable alternative because of the attractive physiological properties of the lungs; the pulmonary epithelium is more permeable and lower enzymatic activity than the gut. In addition, it has a large surface area that is highly vascularised with thin epithelium in the alveolar lung tissue. 3 In addition, the pulmonary epithelium has many immunological properties. 2 Most organisms causing respiratory infections attack the host via the mucosal membrane. Consequently, the non-invasive pulmonary delivery of antigens can provide protection to mucosal membranes at the site of infection and potentially provides a first-line defense against invading microorganism. 4 The extensive dendritic cell (DC) networks that line the respiratory epithelium are considered an ideal target to initiate a strong immune response. 2 Moreover, pulmonary delivery reduces the risk of cross contamination due to the reuse of needles and syringes, and eliminates needle stick injuries, in both patients and medical personnel. 4 Nanoparticles (NPs) are a useful delivery system for pulmonary macromolecules because of their potential for targetted drug delivery, sustained release and reduced dosing frequency, hence improving patient compliance and convenience. 5 They provide an additional advantage for antigen delivery systems, with studies suggesting NPs of about 500 nm or less were optimal for DCs uptake. 6, 7 A most common method for the encapsulation of water-soluble drugs such as protein, peptides and antigens in biodegradable polymer-based NPs is the water-oil-water (w/o/w) double-emulsion solvent evaporation method. 2 Biodegradable poly(glycerol adipate-co-T-pentadecalactone, PGA-co-PDL) has previously been investigated as a novel delivery system of small molecule, for example, dexamethasone phosphate, 8 model drugs, for example, 2 RESEARCH ARTICLE -Pharmaceutical Nanotechnology ibuprofen 9 and sodium fluorescein, 10 and macromolecules, for example, DNase I, 11 via dry powder inhalation (DPIs). However, particles smaller than 1 :m show poor lung deposition and are likely to be exhaled because of their low inertia, whereas particles larger than 5 :m cannot pass the oropharynx effectively. 12 Hence, to achieve particle deposition in the respirable region of the lung, the particles should be in the size range 1-5 :m. NPs can be formulated into microparticle carriers with an aerodynamic diameter between 1 and 5 :m to form nanocomposite microparticles (NCMPs) as DPIs by spray-drying. [13] [14] [15] [16] Spray-drying is a process where the formulation is presented as a feed solution, suspension or emulsion and converted into fine droplets, followed by exposure to rapid hot air-stream resulting in dry respirable-sized powders. In addition to the composition of the feed formulation, several operational parameters greatly affect the quality and quantity of the final formulation such as inlet temperature, air flow, aspiration capacity and feed rate. [17] [18] [19] [20] Biocompatible excipients (carbohydrates, amino acids and lipids) are typically added to the formulation feed to afford dry powders with bulk and to promote the production of a desirable aerodynamic particle size which upon inhalation allows rapid release of NPs in the lung fluid. 10, 13, 17, [21] [22] [23] In addition, the excipients can protect the NPs and encapsulated agents against the extreme spray-drying process conditions such as high temperatures and shear forces. 24 Delivering these microparticle carriers as DPIs via the pulmonary route offer many advantages such as not requiring trained medical personnel, eliminates cold-chain requirements and offers increased physical and chemical stability of macromolecules in comparison with liquid formulations. 4 The Taguchi design is a useful method for studying a large number of parameters and interactions as it has the ability to optimise many parameters simultaneously and extract quantitative data from only a few experiments compared with the traditional factorial design. 25, 26 For example, a single replicate of four parameters and three level experiments would require 81 runs for a full factorial analysis. However, using the Taguchi method will require only nine runs. The Taguchi approach has previously been used in the improvement of dosage forms. 25 Moreover, the Taguchi design concentrates on product robustness against uncontrollable (noise) factors. It employs a signal-to-noise (S/N) ratio to quantify variations. These ratios are meant to be used as measures of the effect of noise (uncontrollable) factors on performance characteristics. S/N ratios take into account both amount of variability in response data and closeness of average response to the target (1). In Taguchi design, S/N ratio can be defined as the measure of the deviation of the response from the desired value. So, 'signal' presents the mean value and 'noise' presents the SD. It means that lower variability in the process is ensured through maximising the S/N ratio (2) . The variability of a characteristic is due to the noise factor such as environmental factors. Thus, optimising process parameters by the Taguchi design leads to bringing the average quality near to the target value, and also to simultaneously decrease the variation in quality (3) . The experimental condition having the maximum S/N ratio is considered the optimum condition, as the variability of characteristics is in inverse proportion to the S/N ratio (4) .
In this study, we have formulated PGA-co-PDL NPs encapsulating bovine serum albumin (BSA), a model protein, using Taguchi design to optimise NPs size and drug loading (DL) for effective uptake by DCs. The PGA-co-PDL NPs were then incorporated into L-leucine microparticle carriers via spraydrying using condition optimised using Taguchi design to produce NCMPs carriers suitable for pulmonary delivery via DPIs, maintaining BSA structure and activity.
MATERIALS AND METHODS

Materials
Q1
Poly(glycerol adipate-co-T-pentadecalactone) (MW of 16.7 kDa) polymer was synthesised and characterised in our laboratory as previously described by Thompson et al. 27 BSA was obtained from (MW 67 kDa) Avenchem, UK. Poly(vinyl alcohol) (PVA; MW of 13-23 kDa, 87%-89% hydrolysed) was obtained from Clariant GmbH, Frankfurt, Germany. Dichloromethane (DCM) was purchased from BDH, Laboratory Supplies, UK. QuantiPro Q2 bicinchoninic acid (BCA) protein assay kit, L-leucine, phosphate buffer saline tablet (PBS; pH 7.4), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), RPMI-1640 medium with L-glutamine and sodium hydrogen carbonate (NaHCO 3 ), tween 80, albumin tagged with fluorescein isothiocyanate (FITC-BSA) were purchased from Sigma-Aldrich, UK. Minimum essential medium (MEM) alpha-nucleosides were obtained from Gibco by Life Technologies, UK. 75 cm 2 /tissue culture flask (vented cap), 96-well flat bottom plates, acetone, antibiotic/antimyotic solution (100×), dimethyl sulfoxide (DMSO) and paraformaldehyde were purchased from Fisher Scientific, UK. CVS10D omniPAGE vertical gel electrophoresis system, protoGel stacking buffer, protein molecular weight markers in the range 10-220 kDa, protein loading buffer blue (2×) [0.5 M Tris-HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) glycerol, 2% (v/v) 2-mercaptoethanol and bromphenol blue in distilled/deionised water], Tris-glycine-sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) buffer (10×) containing 0.25 M Tris base, 1.92 M glycine and 1% (w/v) SDS were purchased from Geneflow Limited, UK. 4-Nitrophenyl acetate esterase substrate (NPAES) was purchased from Sigma-Aldrich. Heat inactivated foetal calf serum (FCS) was purchased from Biosera, UK. Adenocarcinomic human alveolar basal epithelial cell line, A 549 (CCL-185TM) and immature DCs; monocyte, mouse, JAWS II (CRL-11904 TM ) were purchased from American Type Culture Collection (ATCC); 4 ′ ,6diamidino-2-phenylindole, dihydrochloride (DAPI) and Wheat Germ Agglutinin Texas RedR-X conjugate (WGA TR) were purchased from Invitrogen, Ltd., UK.
Experimental Design and NP Preparation
Taguchi design L36 orthogonal array was constructed through Minitab 16 Statistical Software R (Minitab Inc., Pennsylvania). It was composed of eight variables set at two levels or three levels ( Table 1 ). This design was used to identify the important parameters that would influence the NP size and BSA loading. A high signal-to-noise (S/N) ratio indicated the optimum conditions. The signal factor (S) was the outcome, that is, particle size or BSA loading and noise factors (N) included room temperature, humidity, experience of researcher and so on. Optimisation of the particle size and BSA loading was performed using the Taguchi's 'smaller-is-better' and 'larger-is-better' criterion, respectively. 28 Bovine serum albumin-loaded PGA-co-PDL NPs were prepared using a (w/o/w) double emulsion/solvent evaporation method. Briefly, BSA solution containing PVA (internal aque- 
Experimental Design and NCMPs Preparation
A second design was constructed using an L27 orthogonal array design through Minitab 16 Statistical Software R (Minitab Inc.). It composed of five variables each set at three levels ( Table 2 ). Optimisation of yield% was undertaken using the Taguchi's 'larger-is-better' criterion. Spray-drying was used to incorporate the PGA-co-PDL NPs into NCMPs using L-leucine as a carrier. NPs (control and BSA loaded) were suspended in an aqueous L-leucine solution at a polymer-to-carrier ratio of 1:1.5 (w/w) and spray-dried with a Büchi B-290 mini-spray dryer (Büchi Labortechnik, Switzerland) containing a standard two-fluid nozzle (0.7 mm diameter). The dried powder (PGA-co-PDL/L-leucine NCMPs) was separated from the air stream using a high-performance cyclone (Büchi Labortechnik), collected and stored in a desiccator at room temperature prior to further investigations.
NP Characterisation
Particle Size, Polydispersity Index and Zeta Potential.
Samples were analysed by laser diffraction (Zetasizer Nano ZS; Malvern Instruments Ltd., UK). Briefly, 200 :L aliquot of the double emulsion sample was diluted with deionised water (8 mL), and placed into a cuvette with the measurements conducted at ambient temperature (25 • C) (n = 3).
Protein Loading of NPs.
The amount of protein loaded in the NPs was determined by measuring the amount of protein remaining in the supernatant and wash after centrifugation using a QuantiPro BCA protein assay kit (n = 3), by UV spectroscopy at 562 nm (Genesys 5 spectrophotometer; Thermo Fisher Scientific Inc., Waltham, Massachusetts). A calibration curve was obtained with BSA standard solutions (2.5-30 :g/mL) and the DL was calculated according to Eq. 1: DL = actual amount of encapsulated BSA (:g) actual amount of nanoparticles (mg) (1)
NCMPs Characterisation
Particle Size and Morphology.
To ensure the recovery of NPs from NCMPs, 5 mg of NCMPs was suspended in 10 mL deionised water and measurements performed as described in section 1.5.1 (n = 3).
Q3
Scanning electron microscopy (SEM) (FEI-Quanta TM 200 ESEM, Holland) was used to visualise the morphology of NCMPs. Spray-dried NCMPs samples were placed on aluminium stubs (pin stubs, 13 mm) covered with a conductive carbon tab and coated (EmiTech K 550X Gold Sputter Coater, 25 mA) with palladium (10-15 nm) for 3 min.
Yield of Spray-Dried NCMPs.
The percentage yield of dry powder NCMPs was calculated as the mass of expected total powder (n = 3) according to Eq. 2:
%Yeild =
Weight of powder collected after spray drying Weight of total dry mass used for the preparation × 100 (2)
Moisture Content.
Thermogravimetric analysis (TGA Q50, UK equipped with TA universal analysis 2000 software) was used to evaluate the moisture content of dry powder NCMPs after spray-drying. Approximately 10-15 mg of NCMPs was placed in a platinum pan and heated between 25 • C and 650 • C at a purged with nitrogen at 20 mL/min and a scanning rate at 10 • C/min. The moisture content was analysed for data collected between 25 • C and 120 • C.
Powder Density and Primary Aerodynamic Diameter.
The tapped density of selected NCMPs was determined by inserting approximately 0.2 g of powder into a 5 mL graduated cylinder and recording the initial volume. Tapped density measurements were then performed until no change in volume was observed (n = 3). The data obtained from geometric particle size (d) and tapped density (D) was used to determine the theoretical aerodynamic diameter (d ae ) according to Eq. 3. In Vitro Aerosolisation Investigations.
The aerosolisation studies of the NCMPs were evaluated using the next-generation impactor (NGI). Optimum NCMPs formulations (n = 3) were filled into capsules (hydroxypropyl methylcellulose, size 3. 4 capsules each corresponding to 10 mg spraydried powder) and aerosolised via a Cyclohaler R (Teva Pharma) into NGI. The capsules were punctured using the actuator of the Cyclohaler R prior to inhalation at a flow rate of 60 L/min for 4 s. 29 The samples were collected using DCM/0.15 M NaCl mixture (2:1) to extract the BSA from the polymer, which was then analysed by the QuantiPro BCA protein assay as mentioned above. The fine particle dose (FPD) was determined as the total mass of powder deposited in NGI stages with aerodynamic diameters less than 4.5 :m, the fine particle fraction (FPF%) was determined as the fraction of emitted dose deposited in the NGI with aerodynamic diameters less than 4.5 :m, and the mass median aerodynamic diameter (MMAD) was calculated from log-probability analysis.
In Vitro Release Studies.
Nanocomposite microparticles samples (10 mg) were placed in microtubes and dispersed in 1. 
The % cumulative protein release was assessed using zero order, first order and Higuchi's square root plot release models. 30 The correlation coefficient was calculated from the following graphical representations, zero order: % cumulative protein release versus time; first order: log% cumulative protein remaining versus time; Higuchi: % cumulative protein release versus square root of time.
Protein Characterisation
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis.
The primary structure of released BSA from NPs and NCMPs was characterised by SDS-PAGE performed on a CVS10D om-niPAGE vertical gel electrophoresis system with 9% stacking gel prepared using ProtoGel stacking buffer containing 0.4% Coomassie Brilliant Blue was used to stain the gel followed by destaining in distilled water for 24 h. Gel scanner (GS-700 Imaging Densitometer; Bio-Rad) equipped with Quantity One software was used for the gel imaging and documentation.
Circular Dichroism.
The secondary structure of standard BSA (as a control), and BSA released after 48 h from NCMPs in PBS was determined via circular dichroism (CD) using a J-815 spectropolarimeter (Jasco, UK) at 20 • C as reported previously. 31 Five scans were recorded per sample using a 10 mm path-length cells at far-UV wavelengths from 260 to 180 nm at a data pitch of 0.5 nm, band width of 1 nm and a scan speed 50 nm/min. Far-UV CD spectra were collated for standard BSA and BSA released in PBS after 48 h, and the baseline acquired without the sample was subtracted. 32 The secondary structure of the samples was estimated using the CDSSTR method 33 protein reference set 3 from the DichroWeb server. 34, 35 Determination of BSA Activity.
A freshly prepared NPAES solution 36 (15 :L of a 5 mM solution in acetonitrile) was added to the released BSA sample (1.2 mL in PBS, 50 :g/mL) and incubated for 1 h (HulaMixer TM Sample Mixer). The absorbance of the sample mixture was measured at 405 nm with standard BSA (50 :g/mL) used as a positive control and PBS buffer alone as a negative control. The BSA relative residual esterolytic activity was determined as the ratio of absorbance between the released BSA to standard BSA. The esterolytic activity for standard BSA was considered as 100%.
Cell Viability Studies.
A549 cells were cultured in RPMI-1640 medium containing 10% FCS/1% antibiotic/antimycotic solution (complete growth medium-i). DCs were cultured in MEM alpha medium containing ribonucleosides, deoxynucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate 2 mM, supplemented with 20% FCS, 5 ng/mL murine growth GM-CSF and 1% antibiotic/antimycotic solution (complete growth medium-ii).
The toxicity profiles of NPs and NCMPs were assessed over 24 h in A549 and of NPs only over 4 h in DCs using MTT assay. Cells were cultured in 96-well plates with 100 :L 5 (2.5 × 10 5 cells/mL) complete growth medium i and ii, respectively, at 37 • C and 5% CO 2 . Then, complete growth medium (100 :L) containing NPs (0-5 mg/mL) (n = 3) and 10% DMSO as a positive control were added to the wells and incubated for a further 4 h with DCs or with NPs and NCMPs (0-1.25 mg/mL) (n = 3) for 24 h in A549 cells. This was followed by the addition of 40 :L MTT solution (5 mg/mL in PBS, pH 7.4) to each well and incubated for 2 h. The medium was then gently removed (for DCs the 96-well plate was centrifuged at 1300g for 7 min at 4 • C to pellet the suspended cells), and any formazan crystals generated were solubilised with 100 :L of DMSO and the absorbance measured using a microplate reader (Epoch, BioTek Instruments Ltd., UK) at 570 nm. The % cell viability was calculated as the absorbance ratio between NPs or NCMPs-treated and untreated control cells.
In Vitro NPs Uptake into DCs.
Dendritic cells uptake of FITC-BSA NPs was visualised using confocal laser scanning microscopy (CLSM) (Carl Zeiss lsm 710, UK) and image analysis was performed using Zeiss LSM software The DCs (2 × 10 5 cells/400 :L) were plated into an eightwell chambered borosilicate cover glass system, and incubated at 37 • C and 5% CO 2 for 48 h prior to treatment with NPs. The FITC-BSA NPs (40 :g/40 :L) were placed in the wells and incubated as above for 1 h. The suspensions from each well were removed and washed using PBS. Cells were fixed for 15 min with 300 :L of 4% paraformaldehyde in PBS followed by washing with PBS. The cell membranes were counterstained with WGA TR and the nuclei were counterstained with DAPI added to each well and incubated as above for 10 min, followed by washing with PBS. The cells were examined using a CLSM placed on a computer-controlled inverted microscope (Axiovert 200 M BP). Cells were imaged by excitation at a wavelength of 595 nm (red channel for WGA TR), 358 nm (blue channel for DAPI), 488 nm (green channel for FITC-BSA), with a Plan Neofluar 63×/0.30 numerical aperture objective lens.
Statistical Analysis.
Minitab 16 Statistical Software R (Minitab Inc.) was employed for all statistical analysis and graph plotting. The data obtained were analysed statistically by one-way ANOVA with the Tukey's comparison using Minitab 17.1 Statistical Software R (Minitab Inc.). Statistical significant difference was noted when p < 0.05. Data are stated as the mean ± SD.
RESULTS
Optimisation of the BSA-Loaded NPs using Taguchi Design
The Taguchi L 36 orthogonal array design required 36 runs to be performed to ascertain the important factors influencing the NP size and DL and to produce the optimum conditions for each variable to achieve the smallest particle size NPs (SPS NPs), and highest DL NPs (HDL NPs). Table 3 shows the L 36 orthogonal array and the measured NP size and DL. Analysis of the results indicated particle sizes ranging from 216.2 ± 39.9 to 2168.9 ± 1553 nm and DL ranging from 0.8 ± 0.6 to 26.8 ± 5.8 :g/mg were obtained (Table 3) . Figures 1 and 2 show the mean S/N graph of the NP size and DL of BSA, respectively, for each parameter level. The factor with the largest range and corresponding rank (indicating the relative importance compared with other factors) was considered as the significant factor influencing the size or DL.
The optimum conditions, based on the range, rank and S/N graph (Fig. 1 ), for producing SPS NPs according to the Taguchi's 'smaller-is-better' criterion in Minitab R 16 statistical software was A2B2C3D1E1F1G2H2. When this optimised run was performed the measured particle size obtained was 203.0 ± 5.4 nm, which was lower than the minimum particle size of 216.2 ± 39.9 nm prepared using run 29. It is also worth mentioning that the measured BSA loading of SPS NPs was 35.9 ± 2.4 :g/mg. For the production of HDL NPs (Fig. 2 ) using the Taguchi's 'larger-is-better' criterion, the optimal conditions were A2B1C3D1E1F3G3H2 which produced a DL of 43.67 ± 2.3 :g/mg. This was higher than the maximum DL of 26.8 ± 5.8 :g/mg obtained using run 24. The particle size of HDL NPs was 287 ± 24.4 nm.
Optimisation of the Spray-Drying Process using Taguchi Design
Spray-drying was employed to encompass selected NP formulations into NCMPs using L-leucine as a carrier and to enhance powder dispersion. The Taguchi L27 orthogonal array design required 27 runs to be performed to produce the optimum condition for each factor to achieve the highest yield % of dry powder. Table 4 shows the structure of the Taguchi L27 orthogonal array design and the measured dry powder yield % which ranged from no yield to 49.8 ± 0.2%.
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RESEARCH ARTICLE -Pharmaceutical Nanotechnology 1  22  3  2  1  3  1  0  23  3  2  1  3  2  0  24  3  2  1  3  3  0  25  3  3  2  1  1 Figure 3 presents the mean S/N graph of the yield % for each factor level. The factor with the largest range and corresponding rank (indicating the relative importance compared with other factors) was regarded as the significant factor influencing the yield %. Optimum specifications were determined by high S/N ratios. Based on the range, rank and S/N response graph, production of highest dry powder yield % according to the Taguchi's 'larger-is-better' criterion in Minitab 16 statistical software suggested combinations A1B3C3D2E1 (run H- Table 4 ). When run H was performed the dry powder yield % was 50.9 ± 2.3%. Figure 4 represents the SEM photomicrographs of NCMPs and run H regarding the shape and surface morphology, which was irregular and porous microparticle carriers. The selected HDL NPs and SPS NPs were spray-dried using run H parameters (because it produced the highest yield% of powder ∼50%) to produce NCMPs. The formulations were given the following 
Primary Aerodynamic Diameter and In Vitro Aerosolisation Studies for NCMPs
There was no significant difference between NCMPs formulations regarding geometric particle size (HDL: 3.89 ± 0.37 and SPS: 4.69 ± 0.77 :m) (p > 0.05). However, significant difference (p < 0.05) was observed between the NCMPs formulations with respect to tapped density and carr's index. The theoretical aerodynamic diameter (d ae ) was calculated from both these parameters and ranged from 1.45 ± 0.14 and 1.71 ± 0.32 :m (Table 5) indicating the suitability for pulmonary delivery, but no signif- icant difference (p ? 0.05). BSA deposition data obtained from NCMPs ( Table 6 ) indicated there was no significant difference in FPD and MMAD (p ? 0.05), but HDL H NCMPs achieved a significantly higher FPF (p < 0.05) between the formulations examined.
In Vitro Release Studies
In vitro release studies comparing SPS H NCMPs and HDL H NCMPs formulations were performed ( Fig. 5) (Table 7) . Hence, the release of BSA from NCMPs seems to be a diffusion-limited process. Accordingly HDL H NCMPs was selected for further investigation in this study.
Investigation of BSA Structure and Activity
The primary structure of BSA released from NPs and NCMPs was analysed by SDS-PAGE (Fig. 6 ). The BSA standard and molecular weight marker shown in lanes 1 and 5, respectively, revealed a clear band at about 66 kDa. The BSA released from HDL NPs (lane 2) and from HDL H NCMPs (lanes 3 and 4) , showed similar clear banding patterns to the BSA standard (Fig. 6 ). The single lines in the gels provided evidence that the BSA released did not undergo significant covalent aggregation or fragmentation during the formulation methods used. The residual esterolytic activity of the BSA sample was evaluated to be 74.98 ± 5.8% relative to standard BSA.
The secondary structure of BSA was analysed using CD spectroscopy (Fig. 7) . The structure of standard BSA and BSA released, indicated minima at 221-222 and 209-210 nm and a 6 . SDS-PAGE behaviour of BSA released for the assessment of BSA stability. Lanes represent, BSA standard (1), BSA released from HDL NPs (2), BSA released from HDL H NCMPs (3, 4) , and molecular weight (MW) standard markers, BSA (MW 66,000), (5) . Difference in band intensity was due to different loading. maximum at 195 nm for both samples, which is typical for "helical structure. In support of these data, structural analysis showed that BSA was predominantly helical displaying 51.5% helicity (Table 8) , which is in good agreement with Zhang et al. 37 Structural analysis of BSA released displayed double minima at 210 and 222 nm and a further spectra analysis showed a reduced level of "-helical conformation (circa 48.5% helical) ( Table 8 ). Furthermore, a comparison of BSA released with standard BSA showed that the "-helical content decreased by 3%.
Cell Viability Studies and NPs Cellular Uptake by DCs
The unloaded NPs and NCMPs appeared to be well tolerated by the A549 cell line, with a cell viability of 84.63 ± 5% for NPs and 75.7 ± 4% for NCMPs ( Fig. 8 ) at 1.25 mg/mL concentration after 24 h exposure. In addition, the unloaded NPs displayed a cell viability of 86.38 ± 5.5% at 5 mg/mL concentration after 4 h exposure in DCs, indicating good cell viability with increasing NP concentration ( Fig. 9 ). Figure 10 shows the intracellular localisation of FITC-BSAloaded NPs inside DCs after 4 h incubation. The cell wall of the DCs was stained with WGA TR, the nucleus was stained with DAPI and the NPs loaded with FITC-BSA were observed under red, blue and green channels, respectively. The green fluorescence was observed inside the DCs confirming the presence of NPs.
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DISCUSSION Preparation and Characterisation of NPs
The loading capacity of NPs is a critical aspect for delivery as high loading results in greater bioavailability of drug per particle absorbed. 38 A successful drug delivery system should have a high loading capability which will decrease the amount of drug and excipients used for manufacturing the delivery system. Analysis of the results from the Taguchi design indicated that the DL of NPs was influenced by different parameters in the following order: BSA concentration > IAP volume > polymer mass > PVA concentration > OP volume > EAP sonication time and IAP sonication time > sonication amplitude; whereas the influence on the particle size of NPs had the following order: polymer mass > OP volume > sonication amplitude > surfactant concentration > EAP sonication time IAP sonication time > IAP volume > BSA concentration. Bovine serum albumin concentration (rank 1; Fig. 2 ) had the greatest influence on the DL which increased profoundly as the BSA concentration increased from 0.2% to 1%. This was expected from predictions based on Eq. 1 in which DL is positively proportional to the amount of BSA 38 and can be seen comparing run 7 (4.1 ± 0.6 :g/mg) and run 18 (15.7 ± 4.8 :g/mg). However, increasing the BSA concentration to large levels (1%) is not necessarily beneficial; this trend has been explained by the mass of polymer used being insufficient to completely encapsulate the BSA. 38 Furthermore, higher concentrations of BSA provide a higher concentration in IAP droplets and thus increase the concentration gradient between the IAP droplets and the EAP, resulting in an increased amount of BSA transported into the EAP. 39, 40 IAP volume (rank 2; Fig. 2 ) plays an important role on DL, such that, the larger volume of the IAP the higher the BSA loading, as seen in run 13 (1.4 ± 0.5 :g/mg) and run 19 (5.0 ± 0.1 :g/mg) ( Table 3 ). This effect has been reported 38, 41 and is thought to be due to a decrease in the concentration gradient between IAP and EAP.
The third factor affecting DL was the polymer mass (rank 3; Fig. 2 ). DL decreased substantially with increasing polymer mass from 50 to 200 mg, as predicted based on Eq. 1, in which DL is inversely proportional to the polymer mass. 42 This trend can be seen in run 22 (5.6 ± 0.04 :g/mg) and run 25 (2.8 ± 0.1 :g/mg). In addition, the results showed that reducing the OP volume (rank 5; Fig. 2 ) increased DL. This was associated with the high viscosity of the OP resulting in enhanced primary emulsion stabilisation and minimising the diffusion rate of BSA through the OP. 41 The fourth factor affecting DL was PVA concentration, with 1% PVA resulting in higher BSA loading as seen comparing run 19 (5.0 ± 0.1 :g/mg) and run 22 (5.6 ± 0.04 :g/mg) (Fig. 2) . A possible explanation was that at this concentration PVA was adequate to completely cover the partition interface (organic/aqueous) and subsequently resulting in reduced leaching of BSA. Consequently, any further increase in PVA concentration (5% and 10%) resulted in decreased DL because of the enhanced partitioning of BSA into the aqueous phase during emulsification. This was attributed to the solubilisation and emulsification effect of PVA. 43 Sonication time of the EAP and IAP exerted similar effects on DL where increasing the sonication time of IAP and EAP resulted in higher DL. 44 The factor that had the least effect was sonication amplitude. Increasing the sonication amplitude (30% to 45% to 65%) had almost no beneficial effect on the BSA loading. This effect has been reported previously and has been associated with BSA precipitation within the sonication probe due to high pressure and increased fluid cavitations during sonication. 45, 46 Analysis of results following the Taguchi design indicated that the particle size of NPs was influenced by different parameters in the following order: polymer mass > OP volume > sonication amplitude > surfactant concentration > EAP sonication time and IAP sonication time > IAP volume > BSA concentration. It can be seen that the polymer mass followed by the OP volume (rank 1 and 2; Fig. 1 ) had the greatest effect on NPs size. An increase polymer mass resulted in an enhanced NP size, with run 3, 6, 9, 20 and 23 achieving the largest NPs size (Table 3 ). This was demonstrated by the observation that PGA-co-PDL mass was the primary parameter accountable for the variation in NPs size. A similar observation has also been noted by Bilati et al. 38 investigating PLGA NPs encapsulated with protein prepared using a double emulsion solvent evaporation method or with microparticles. The effect of polymer mass on the particle size has also been attributed to the increased viscosity and subsequent less proficient stirring of the OP leading to an greater NPs coalescence. 47 Poly(vinyl alcohol) concentration was directly proportional to size with a trend of 1 < 5 < 10% PVA (rank 4; Fig. 1 ). This was associated with an increase in viscosity with increase in PVA concentration in the IAP corresponding to a reduced shear stress, decreased diffusion rate and consequently increase in NP size. This can be seen comparing run 4 (1% PVA, 498.7 ± 4.6 nm) and run 7 (5% PVA, 577.8 ± 107.4 nm) (Table 3 ). Furthermore, additions of more PVA lead to an enlargement in NPs size because of the buildup of surplus molecules at the surface leading to bridging between the primary particles. 43 BSA concentration and IAP volume had minimum effect on the particle size of NPs which has also previously been reported in literature. 38 The rate of size reduction decreased considerably when sonication was carried out beyond the duration of 5 s for IAP (rank 6) or 15 s for EAP (rank 5) or beyond the amplitude (rank 3) of 45% ( Fig. 1 ). Increasing amplitude lead to more fluid cavitation, this inhibits the efficiency of energy transmission and decreased ultrasonic effect. 48 This can be seen in run 10 and 29 (Table 3 ) which differ in amplitude (65% and 45%, respectively), sonication time for IAP (10 and 15 s, respectively) and EAP (10 and 30 s, respectively) Precise adjustment of the numerous formulation and processing factors is important to attain the desired NPs size and BSA loading. In this study, a particle size of ≤500 nm was desired to facilitate uptake of NPs by DCs. 6, 7, 49 A high S/N ratio suggested optimum conditions such that, the larger the S/N ratio, the less variance of particle size and BSA loading from the desired value. When the suggested optimized run was carried out, the measured particle size (SPS NPs) obtained 203 ± 5.4 nm was considered suitable for DCs uptake. [50] [51] [52] 
NCMP Characterisation
Spray-drying was utilised to encompass the selected NPs into NCMPs with L-leucine as a carrier and to enhance powder dispersion. Majority of the spray-drying process parameters achieved low yields because of the condensation inside the drying chamber and collecting vessel resulting in the dry particles sticking to the walls. 53 Utilising the Taguchi design revealed that the feed rate, aspirator capacity, air flow and inlet temperature had the greatest effects on the yield% of dry powder, whereas the change in the concentration of total solid in the spray-dried suspension had no effect in the yield% of dry powder.
The most important factor was feed rate (rank 1; Fig. 3 ) with a negative effect on powder yield. At high feed rates 15%, it is difficult for the atomized air to penetrate the liquid stream. Consequently, insufficient atomisation and drying will result with large NCMPs deposition and sticking to the walls in the drying and cyclone chambers. 53 The second important factor was aspirator flow (rank 2; Fig. 3 ) with a positive effect on powder yield% (rank 2). A high aspirator flow rate created greater centrifugal force leading to an increase in the collection efficiency. 54 Airflow had a negative effect on powder yield% (rank 3; Fig. 3 ). Higher spray flow produced smaller droplets which were collected less efficiently by the centrifugal force in the cyclone. 54 The inlet temperature (rank 4; Fig. 3 ) of drying air ranged from 50 • C to 100 • C, typically resulting in an outlet temperature of approximately 22 • C to 46 • C. It was noticed that as the inlet temperature increased from 50 • C to 100 • C there was an increase in powder yield%. It has been reported that a high inlet temperature can reduce the drying time and inhibit particle aggregation. 55 Furthermore, a higher inlet temperature promotes a decrease in residual moisture by enhancing water evaporation resulting in less particles sticking in the drying chamber. 56 The results obtained from spray-drying regarding runs 10, 11, 12, 22, 23 and 24 produced no yield. They all shared the predominant factor (Feed Rate, rank 1; Fig. 3 ) affecting yield although they differed in other factors (aspirator capacity, air flow and inlet temperature) ( Table 4 ). The feed rate was 15%, and at this high rate the atomising air may not be able to break the flow of the suspension. Furthermore, the high feed rate was accompanied by low level of aspirator capacity (50% and 75%), high level airflow (535 and 670 L/h) and low level of inlet temperature (50 • C and 75 • C), which all had negative effect on yield as explained above. When these parameters were adjusted to their positive level in run 7, 8 and 9 ( Table 4 ) the yield increased up to 43%.
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Photomicrographs showed irregular and porous NCMPs. This has been associated with vapour pressure that builds up during the removal of water throughout spray-drying and is prevalent with L-leucine and other hydrophobic amino acids, resulting in improved aerosolisation. 57 Furthermore, photomicrographs of NCMPs were similar irrespective of different processing conditions. High residual moisture content can promote particle aggregation leading to a variation in particle size distribution. 58 The low moisture content reported from the TGA thermogram presents a good drying efficiency therefore the dry powder formulations are likely to show good storage stability.
In Vitro Release and Aerosolisation Studies
Aerosolisation deposition data of NCMPs formulations indicated a similarity in FPD. The significantly higher FPF% of HDL H NCMPs compared with SPS H NCMPs was attributed to powder aggregation which was demonstrated by the large Carr's index, ≥32, implying the flow of SPS H NCMPs was very poor. In addition, SPS H NCMPs had a significantly smaller MMAD indicating possibility of aggregation and
In vitro release studies comparing SPS H NCMPs and HDL H NCMPs formulations were performed, with our results indicating a diffusion-limited process according to the Higuchi diffusion model. The observed change in release profile at 24 h following the initial burst release could be attributed to the distribution of BSA within NPs and/or alteration in degradation rate due to changed surface porosity. 24
Stability of BSA and Cell Viability Studies
The primary structure of BSA released from HDL NPs and HDL H NCMPs showed similar clear banding patterns to the BSA standard provided evidence that the released BSA did not suffer significant covalent aggregation or fragmentation during the preparation methods used.
The secondary structure of BSA released was analysed using CD spectroscopy, a valuable technique in analysing the protein structure. 31 The spectra confirmed the presence of "-helix in the BSA released samples although this was decreased in comparison with standard BSA.
Bovine serum albumin has an enzyme-like activity and is able to hydrolyse substrates such as p-nitophenyl esters. 36 When compared with standard BSA, the released BSA sample maintained approximately 74% of relative residual esterolytic activity, which was higher than 60% obtained by Abbate et al. 36 The reduction seen in this study was possibly due to the encapsulation process which resulted in a reduction in helicity as evaluated by CD ( Fig. 7 and Table 8 ), and hence BSA activity. However, a 74% retention in activity achieved using this delivery system is still promising for further investigation of macromolecule delivery including proteins for vaccine.
The influence of NPs and NCMPs on cell viability studies were performed on the A549 and JAWS II DC lines. The NPs and NCMPs appear to be well tolerated by both cell lines. Although a decrease in cell viability was observed with increasing NPs and NCMPs concentration in both cell lines (A549: >75% at 1.25 mg/mL and DC: >85% at 5 mg/mL concentration), a high DL was obtained, which indicates lower doses could be delivered, hence negating the potential toxicity at high doses. Moreover, the dose delivered would be distributed throughout the lung and not localise within specific sites at these high concentrations. 59 The uptake of NPs by JAWS II DC type was confirmed by CLSM. Thus NPs are efficiently ingested by DCs and could be applied for the delivery of antigens to DCs.
CONCLUSIONS Q5
The PGA-co-PDL NPs with appropriate size (203 ± 5.4 nm) to target DCs and BSA loading (43.67 ± 2.3 :g/mg) were successfully prepared using the Taguchi L36 orthogonal array design of experiment method. Selected NPs formulations were incorporated into NCMPs using L-leucine as a carrier. The highest yield% of dry powder (50%) was obtained using the Taguchi L27 orthogonal array design of experiment. The NCMPs had irregular and porous surface. The in vitro release studies indicated BSA maintains its primary and secondary structure. Furthermore, aerosolisation deposition data (FPF 78.57 ± 0.1% and MMAD 1.71 ± 0.1 :m) indicate deep lung deposition. In addition, the NPs and NCMPs had a relatively high cell viability (A549: >75% at 1.25 mg/mL and DC: >85% at 5 mg/mL concentration) at high concentrations. This study suggests that PGAco-PDL NCMPs could be further investigated for pulmonary delivery of macromolecules, including the possibility for vaccine delivery via the pulmonary route.
